AKUMSNSEAKUMS DRUGS AND PHARMA LMediumNeutral
Announced Thu, 13 Aug · 14:40 IST

Q1 FY27 Earnings Call: Revenue Up 14%, EBITDA Up 35%, Confident on FY27

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.4%1-day move
₹750.00
prior close
₹753.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0-0.0-0.0-0.1-3.4-0.9-0.6+0.0+0.0
Up moveDown movePending
AI summary

Q1 FY27: Revenue up 13.9% YoY to INR1,167 cr. EBITDA up 35.4% to INR175 cr at 15% margin (up 238 bps). PAT up 56% to INR101 cr. CDMO drove growth at 18.6% revenue rise with better API prices. Net cash INR1,616 cr. Guides CDMO margins at upper end of 14-15%, volumes in high teens. Zambia order worth about $25 million expected in H2 FY27. New Baddi facility to go live by year-end. API losses narrowing.

Likely market impact

Strong quarter with margin expansion. Healthy cash and capacity. Watch Zambia execution, new Baddi plant ramp-up, and Akumentis field force productivity.